Christophe Duvoux

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9395715/publications.pdf

Version: 2024-02-01

40 papers 3,491 citations

331670 21 h-index 302126 39 g-index

41 all docs

41 docs citations

41 times ranked

4733 citing authors

#	Article	IF	CITATIONS
1	Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria. Gastroenterology, 2012, 143, 986-994.e3.	1.3	736
2	Impact of UCSF criteria according to pre- and post-OLT tumor features: Analysis of 479 patients listed for HCC with a short waiting time. Liver Transplantation, 2006, 12, 1761-1769.	2.4	405
3	2018 Annual Report of the European Liver Transplant Registry (ELTR) - 50-year evolution of liver transplantation. Transplant International, 2018, 31, 1293-1317.	1.6	325
4	Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. Journal of Hepatology, 2016, 65, 524-531.	3.7	298
5	Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transplantation, 2005, 11, 767-775.	2.4	216
6	Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study. Journal of Hepatology, 2019, 71, 313-322.	3.7	212
7	Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. Journal of Hepatology, 2018, 69, 810-817.	3.7	199
8	Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. Journal of Hepatology, 2017, 66, 552-559.	3.7	166
9	Protective Role of Tacrolimus, Deleterious Role of Age and Comorbidities in Liver Transplant Recipients With Covid-19: Results From the ELITA/ELTR Multi-center European Study. Gastroenterology, 2021, 160, 1151-1163.e3.	1.3	130
10	COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry. The Lancet Gastroenterology and Hepatology, 2020, 5, 724-725.	8.1	72
11	Liver transplantation for hepatocellular carcinoma: evaluation of the alphaâ€fetoprotein model in a multicenter cohort from Latin America. Liver International, 2016, 36, 1657-1667.	3.9	71
12	ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. Journal of Hepatology, 2017, 67, 585-602.	3.7	71
13	Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: A multicenter study of 412 patients. World Journal of Gastroenterology, 2006, 12, 7319.	3.3	70
14	Delisting <scp>HCV</scp> â€infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting. Liver International, 2018, 38, 2170-2177.	3.9	54
15	Impact of COVIDâ€19 on liver transplantation in Europe: alert from an early survey of European Liver and Intestine Transplantation Association and European Liver Transplant Registry. Transplant International, 2020, 33, 1244-1252.	1.6	48
16	Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma. Journal of Hepatology, 2018, 69, 336-344.	3.7	47
17	Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors. Digestive and Liver Disease, 2015, 47, 869-876.	0.9	46
18	Survival of children after liver transplantation for hepatocellular carcinoma. Liver Transplantation, 2018, 24, 246-255.	2.4	32

#	Article	IF	CITATIONS
19	Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation. Journal of Hepatology, 2021, 75, S178-S190.	3.7	30
20	Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients. Liver Transplantation, 2006, 12, 1489-1495.	2.4	27
21	2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virusâ€related infection before and after liver transplantation. Alimentary Pharmacology and Therapeutics, 2021, 54, 583-605.	3.7	27
22	Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series. Digestive and Liver Disease, 2018, 50, 668-674.	0.9	24
23	Temporal Trends and Outcomes in Liver Transplantation for Recipients With HIV Infection in Europe and United States. Transplantation, 2020, 104, 2078-2086.	1.0	24
24	Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with <i>de novo</i> carcinoma. International Journal of Cancer, 2019, 144, 886-896.	5.1	22
25	Functional imaging of hepatocellular carcinoma using diffusion-weighted MRI and 18F-FDG PET/CT in patients on waiting-list for liver transplantation. Cancer Imaging, 2016, 16, 4.	2.8	21
26	Early transplantation maximizes survival in severe acute-on-chronic liver failure: Results of a Markov decision process model. JHEP Reports, 2021, 3, 100367.	4.9	21
27	Predictive Factors for Survival in Children Receiving Liver Transplants for Wilson's Disease: A Cohort Study Using European Liver Transplant Registry Data. Liver Transplantation, 2018, 24, 1186-1198.	2.4	15
28	What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma?. Liver Transplantation, 2011, 17, S147-S158.	2.4	13
29	12 Weeks of a Ribavirinâ€Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation. Hepatology, 2018, 68, 1277-1287.	7.3	11
30	Liver transplantation in patients with sickle cell disease: possible but challenging—a cohort study. Transplant International, 2020, 33, 1220-1229.	1.6	10
31	International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria. JHEP Reports, 2021, 3, 100331.	4.9	10
32	Direct-acting antiviral agent–based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study. American Journal of Transplantation, 2017, 17, 2869-2878.	4.7	6
33	Influence of everolimus-based treatment on circulating regulatory T cells after liver transplantation: Comparative study with tacrolimus-based therapy. Clinics and Research in Hepatology and Gastroenterology, 2020, 45, 101559.	1.5	6
34	Socioeconomic Deprivation Does Not Impact Liver Transplantation Outcome for HCC: A Survival Analysis From a National Database. Transplantation, 2021, 105, 1061-1068.	1.0	6
35	R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation. JHEP Reports, 2022, 4, 100445.	4.9	6
36	Liver Resection for Solitary Transplantable Hepatocellular Carcinoma: The Role of AFPâ€Score. World Journal of Surgery, 2019, 43, 221-229.	1.6	5

3

#	Article	IF	CITATIONS
37	A Multicenter, Prospective, Observational Study of Conversion from Twice-Daily Immediate-Release to Once-Daily Prolonged-Release Tacrolimus in Liver Transplant Recipients in France: The COBALT Study. Annals of Transplantation, 2019, 24, 506-516.	0.9	5
38	Anonymous living donation in liver transplantation: Squaring the circle or condemned to vanish?. Journal of Hepatology, 2019, 71, 864-866.	3.7	3
39	Reply to Rodriguezâ€PeralvarezÂet al. Transplant International, 2020, 33, 1825-1826.	1.6	1
40	Comment on "Shadows Behind Using Simple Risk Models in Selection of Hepatocellular Carcinoma Patients for Liver Transplantation― Annals of Surgery, 2021, 274, e832-e833.	4.2	0